The induction of peripheral tolerance may constitute a disease-modifying treatment for allergic patients. We studied how oral immunotherapy (OIT) with milk proteins controlled allergy in sensitized mice (cholera toxin plus milk proteins) upon exposure to the allergen. Symptoms were alleviated, skin test was negativized, serum specific IgE and IgG1 were abrogated, a substantial reduction in the secretion of IL-5 and IL-13 by antigen-stimulated spleen cells was observed, while IL-13 gene expression in jejunum was down-regulated, and IL-10 and TGF-β were increased. In addition, we observed an induction of CD4 + CD25
Introduction
The prevalence of food allergies has increased over the last decade and constitutes a highly morbid disorder. [1] . The restriction diet represents the current treatment for milk-allergic children, but it may be difficult to comply for multiple reasons: misunderstanding or incomplete information in food labeling, nutritional inadequacy of dairy substitutes, growth retardation, eating disorders and psychosocial problems [2] . For this reason, efforts have been made to develop alternative therapies that complement the avoidance strategy and restore an adequate immune management of food antigens. As there are no currently approved and standardized therapies for food allergies, patients are instructed to strictly avoid the allergenic food and ensure a ready access to epinephrine and anti-histamine [3] .
Evidence of a lack of oral tolerance in food allergic patients [4, 5] has increased the interest in oral immunotherapy (OIT) as an option for a disease-modifying therapy. Although it is an experimental treatment, several clinical trials have shown promising results. However, safety and efficacy are not yet shown and further research is needed to identify the network of regulatory pathways that are induced to limit the tissue inflammation [6, 7] . Although OIT has shown to be effective in inducing clinical desensitization to some food allergens, the mechanisms underlying these therapeutic procedures have not been completely described [8] . OIT to cow´s milk allergy has been actively investigated [9] [10] [11] and, despite periods of withdrawals, it was shown that no symptoms were provoked following milk ingestion [12, 13] . It is known that food-specific regulatory T cells are generated in the gastrointestinal tract, although the exact mechanism of action has not been unveiled [14] .
Dissecting the mechanisms underlying this phenomenon in food allergies is difficult in humans, and animal model studies provide new clues for understanding and controlling the immune response in the compromised mucosa. In this work, we used an IgE-mediated mouse model of food allergy to study the local and systemic regulatory mechanisms of protection promoted by OIT. The repeated oral administration of cow's milk proteins (CMP) induced lamina propria regulatory T cells that controlled the allergic reaction towards oral antigens through the production of IL-10 and TGF-β. The adoptive transfer of CD4 + CD25 + FoxP3 + Treg confined the protection mechanism and the depletion of CD25 + T cells resulted in pronounced disease exacerbation, thus confirming that Treg have an essential role in resolving food allergy in our model.
Materials and Methods

Ethics statement
All experimental protocols of this study were conducted in strict agreement with international ethical standards for animal experimentation (Helsinki Declaration and its amendments, Amsterdam Protocol of welfare and animal protection and National Institutes of Health, USA NIH, guidelines: Guide for the Care and Use of Laboratory Animals). Anesthetized mice (isoflurane 5%) were killed by cervical dislocation by experienced research personnel, which performed it humanely and affectively. All efforts were made to alleviate suffering during the whole experiment. The protocols of this study were approved by the Institutional Committee for the Care and Use of Laboratory Animals from University of La Plata (Protocol Number: 017-00-15).
Animals, sensitization and challenge
Male 6-to 8-week old BALB/c mice were sensitized according to Smaldini et al. [15] . Briefly, mice received 6 weekly intragastric (ig) doses of 20 mg of skimmed CMP and 10 μg of cholera toxin (CT) (Sigma Aldrich, St. Louis, USA) in bicarbonate buffer per mouse (n = 6/group). Ten days after the final boost, mice were ig challenged with 10 mg of CMP on two consecutive days. Twenty-four hours later animals were sacrificed by cervical dislocation. Control group of mice received only 20 mg CMP (without CT) during the sensitization phase and 10 mg during the treatment phase. The experimental design is shown in Fig 1A. Oral administration of CMP as treatment
Mice were divided into two groups for treatment: those who received 10 mg/mouse/day of CMP by gavage during five days prior to sensitization (CMP prev ), and those who were sensitized and then treated with CMP ig (10 μg/mouse/per dose) once per week for 8 weeks (CMP des ). Control groups of mice consisted of mice receiving PBS ig instead of CMP (PBS prev and PBS des ) (Fig 1A) . In addition, as a control of specificity other mice preventively received OVA (5 mg/per dose) and then were sensitized with CMP plus CT as described (OVA prev ). Animals were grouped in 6 mice per condition and experiments were repeated at least twice.
In vivo evaluation of the allergic reaction
Clinical symptoms. Symptoms were observed 45 minutes after challenges with CMP ig in a blinded fashion by 2 independent investigators (Table 1) .
Cutaneous tests. Mice were injected with 20 μg of CMP in 20 μl of sterile saline in one footpad, and saline, in the contra-lateral footpad as a negative control. Then, mice were injected intravenously (iv) with 100 μl of 0.1% Evans blue dye (Anedra, Buenos Aires, Argentina). The presence of blue color 10-20 minutes after the injection was considered a positive test and footpad swelling was measured with a digital micrometer.
In vitro evaluation of the allergic reaction Serum specific antibodies. CMP-specific IgE was measured by EAST, and IgG1 and IgG2a were measured by ELISA as previously described [15] [16] [17] [18] . All samples were run in the same experiment.
Cytokine response of spleen cells to antigen stimulation. 4x10 6 spleen cells/ml were plated in complete medium (RPMI-1640 supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin) with CMP (350 μg/ml) for 72 hours. Cytokines (IL-5, IL-13, IFN-γ) were measured in supernatants by ELISA (Invitrogen, Carlsbad, CA, USA) (17) . Cytokine quantification by ELISA in the jejunum. Frozen sections of jejunum were minced and cells were treated with lysis buffer (10 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 10% Glycerol, 5 mM EDTA and a protease inhibitor cocktail-Sigma). Homogenate was sonicated and the supernatant was collected. IL-10 and TGF-β were determined by ELISA (eBioscience, San Diego, CA, USA).
Real time RT-PCR for gene expression. The mRNA expression was determined by realtime quantitative PCR on an ABI prism sequence detection system using SYBRGreen fluorescence (BioRad, Hercules, CA, USA). β-actin was used as a housekeeping gene and the fold change in the mRNA expression was defined as the ratio of the normalized values in sensitized mice to that in control mice, as previously described [19] . The genes of interest were: IFN-γ, IL-5, IL-13, IL-10, TGF-β and FoxP3.
Cell isolation from gut. Cells were isolated from lamina propria (LP) as described in [20] . Briefly, the entire gut was removed from mice and the second half of the small bowel was excised (jejunum). The epithelial compartment was removed (incubation with HBSS and EDTA 1mM) and then tissue was treated in complete RPMI-1640 medium with 1mg/ml of collagenase and 10U/ml of DNAse. Cell debris were removed by filtration and the cell suspension was used to characterize lamina propria cells. Cells from mesenteric lymph nodes (MLN) were obtained by digestion with collagenase in RPMI for 30 minutes at 37°C. Cell suspensions were filtered and washed in RPMI. Flow Cytometry for Cell Characterization: Cells from MLN and LP were stimulated with recombinant mouse IL-2 (20 ng/ml, Preprotech, NJ, USA) for 12 hs at 37°C with 3 μg/ml of Brefeldin A (eBioscience) added for the last 4 hs to prevent egress of newly synthesized proteins from endoplasmic reticulum. Cells were washed and stained for anti-CD4 (PerCyP 5.5) and anti-CD25 (PE or FITC) (eBioscience). Cells were washed and pre-incubated with fixation/permeabilization solution (eBioscience) 20 minutes at 4°C. For intracellular staining cells were treated with Staining Intracellular kit (eBioscience) and anti-FoxP3 (APC or PE), anti-IL-10 (APC) or anti-TGF-β (APC) (eBioscience). Fluorescence acquisition was performed with a FACScalibur cytometer using QuestProCell software. The gating strategy for cell analysis consisted on a lymphocyte gate based on SSC-H vs FSC-H parameters, followed by SSC-H vs CD4 fluorescence or followed by CD25 vs CD4 fluorescence. The CD4 + lymphocyte population was gated as CD25 vs FoxP3, and CD4 + CD25 + lymphocyte population was gated as FoxP3 vs IL-10 or TGF-β expression. The data were analyzed with the FlowJo software.
Adoptive cell transfer for acquired tolerance in sensitized mice
Peripheral inducible Treg were generated in vitro or in vivo and then transferred to naïve animals, which were then sensitized as described.
In vitro generation of TGF-β-induced regulatory T cells (Tregs).
Spleen was removed from naïve mice, cell suspension was prepared and CD4 + CD25 -cells were aseptically sorted (BD FACS Aria II) using anti-CD4 and anti-CD25 antibodies (eBioscience). Sorted cells were stimulated with anti-CD3/anti-CD28 (2.5 μg/ml and 2 μg/ml respectively; eBioscience) in the presence of IL-2 (20 ng/ml, Preprotech) and TGF-β (5 ng/ml, Preprotech) for 5 days. The phenotype of ex vivo generated Treg cells was analyzed by flow cytometry (FoxP3 and CD25 expression) and ELISA (IL-10 concentration in the supernatant of differentiated cells). For induction of tolerance 1x10 6 differentiated cells were iv injected into recipient mice, which were then sensitized as described (n = 5/group).
In vivo induction of regulatory T cells. Donor mice were daily administrated CMP (10 mg/mouse) or saline during 5 days, and then sensitized with CMP plus CT as described. Lymphocytes isolated from MLN were iv injected (4x10 6 cells) into recipient mice, which were then sensitized as described. Other recipient mice received MLN cells from sensitized donor mice treated with PBS ig as control.
To confirm whether CD4 + CD25 + Treg mediated regulatory mechanisms that reversed the allergic response in sensitized mice, CD25 + cells were depleted prior to adoptive cell transfer.
Cells isolated from sensitized mice (PBS prev ) as control (with low number of Treg) or tolerized mice (CMP prev ) (with high number of Treg) were ex vivo incubated with rat anti-mouse CD25 (eBioscience) or rat IgG isotype (eBioscience) plus rat serum during 40 minutes at 4°C. The remaining cells were washed and the phenotype was analyzed by flow cytometry. Cells were injected into recipient naïve mice (n = 5/group) which were then sensitized as described. As additional control, recipient mice were injected with saline and then sensitized.
Statistical analysis
All the statistical analyses were performed using GraphPad Prism 5 software. The significance of the difference was determined using an independent-sample t-test or ANOVA followed by Bonferroni`s post-test. A p-value <0.05 was regarded as statistically significant.
Results
The intragastric administration of CMP ameliorated the allergic reactions
We followed two immunomodulatory strategies: prevention (CMP prev ) and desensitization (CMP des ) (Fig 1 A) . Animals were sensitized with milk proteins and hypersensitivity reactions observed immediately after the oral challenges with CMP were scored (Fig 1B) . At day 45, sensitized mice exhibited clinical signs corresponding to allergic sensitization (PBS prev , PBS des and CMP des ), whereas control mice showed no symptoms. At this time point, CMP prev mice were protected from allergy and CMP des mice showed a high score (desensitization treatment started at day 52). After the first round of treatment (day 80), CMP des mice still showed high scores; and following the second round of treatment (day 115), CMP des mice presented a diminished average clinical score. In addition, mice pre-treated with OVA (OVA prev ), and then sensitized with CMP plus CT, showed similar scores to sensitized mice. In concordance with these findings, we showed the presence of IgE-sensitized mast cells in the footpads of mice. As shown in Fig 1C, skin tests were positive in sensitized (PBS prev and PBS des ) and OVA prev mice, whereas CMP prev and CMP des mice showed negative results. Footpad swelling was statistically lower in CMP-treated mice compared with sensitized mice (0.54±0.04, 0.07±0.02, 0.46±0.05, and 0.07±0.01 PBS prev , CMP prev , PBS des and CMP des , respectively) or OVA prev mice (0.43±0.03).
Systemic and mucosal Th2-biased specific immune responses were controlled with the intragastric administration of CMP in sensitized mice Serum CMP-specific immunoglobulins and cytokines secreted by CMP-stimulated spleen cells were studied (Fig 2) . CT-driven sensitization (PBS prev and PBS des ) induced sustained high milk-specific IgE and IgG1 antibodies with no induction of specific IgG2a, even 80 days after sensitization. Control mice and pre-treated animals showed no increase in any serum specific isotype. CMP des mice showed a reversion of specific IgE secretion after the second round of treatment. Besides, treated animals showed no significant induction of serum CMP-specific IgG2a level. OVA prev mice showed the same serum pattern as PBS prev (data not shown).
Cytokine analysis showed that the levels of Th2 cytokines were significantly controlled in orally treated mice. As seen in Fig 2B, milk-stimulated spleen cells of sensitized mice (PBS prev and PBS des ) secreted elevated amounts of Th2 cytokines (IL-5 and IL-13), which were significantly suppressed in treated animals. Levels of IFN-γ were low in all animals.
To address the effect of CMP ig administration on the intestinal mucosa we assessed the gene expression corresponding to IL-5, IL-13, IFN-γ, IL-10, TGF-β and Foxp3 in jejunum (Fig 3A) . Sensitized mice (PBS prev and PBS des ) displayed increased expression of IL-5 and IL-13 compared with control mice (fold change of gene expression relative to control mice is depicted). Treatments with CMP ig (CMP prev and CMP des ) significantly abrogated the CT-driven induction of IL-5 and IL-13, with a significant induction of IFN-γ, IL-10 and TGF-β. In addition, these mice showed increased levels of FoxP3 (Fig 3B) . When suppressor cytokines were analyzed at the protein level we found that IL-10 was increased in jejunum of CMP prev and CMP des mice. TGF-β was significantly augmented only in CMP des mice (Fig 3B) .
The intragastric administration of CMP induced intestinal Tregs
Based on previous findings we analyzed the presence of Tregs in lamina propria by flow cytometry. As shown in Fig 4A we (Fig 5A) , which secreted 173.68±5.21pg/ml of IL-10 (CD4 + CD25 -spleen cells produced 17.87±1.2pg/ml of IL-10).
These cells were injected into receptor naïve mice (1x10 6 cells) which were subsequently sensitized. After the oral challenge, mice exhibited lower clinical scores, negative skin test and lower Orally-Induced Treg Control Food Allergy serum CMP-specific IgE (Fig 5Bc) , compared with control mice that received PBS iv prior to sensitization (Fig 5Bb) . An additional control consisted of naïve mice that only received PBS iv and displayed a negative skin test, and low clinical score and serum CMP-specific IgE (Fig  5Ba) .
In vivo-induced regulatory T cells. MLN cells of PBS prev or CMP prev mice were isolated and analyzed for the presence of Tregs. We found a higher percentage of CD4 + CD25 + FoxP3 + cells in CMP prev compared to PBS prev mice ( Fig 5C) . Cells were incubated with a-CD25 or isotype control for CD25 depletion (including Treg) (Fig 5D) , and then were iv administered into naïve recipient mice (4x10 6 cells), which were subsequently sensitized. As additional control, naïve mice received PBS iv prior to sensitization. We observed in mice that received PBS and were then sensitized, that the oral challenges induced high clinical scores, positive skin tests and serum specific IgE antibodies (Fig 5Ea) . Similarly, mice that were transferred with MLN cells from sensitized animals (PBS prev ) that were treated with a-CD25 or isotype control (Fig 5Eb and c) , or mice that received a-CD25-treated MLN cells from tolerized animals (CMP prev ) (Fig 5Ed) exhibited hypersensitivity symptoms, positive skin test and high levels of serum specific IgE. Finally, naïve animals that were transferred with isotype-treated cells from tolerized mice (CMP prev ) showed low clinical score, negative skin tests and serum specific IgE antibodies (Fig 5Ee) .
In addition, MLN cells of CMP prev mice stimulated with CMP rendered 587±23 pg/ml of IL-10 and 1558±257pg/ml of TGF-β, while MLN cells from control mice incubated with CMP rendered 121±35 pg/ml of IL-10 and 88±14pg/ml.
Discussion
Strict allergen avoidance is currently the primary therapy for managing IgE-mediated and non-IgE-mediated food allergy, but in the last two decades there has been increasing interest in optimizing mucosal immunotherapies [8] . Compelling evidences indicate that a step-dose administration of milk proteins through the oral route in patients induces immune tolerance [21] . The immunologic mechanisms underlying OIT is not fully understood. Although there is great heterogeneity in the design of these studies (age, symptoms, randomization, duration, etc.), it has been shown that the cumulative dose of food allergens that patients can tolerate is 200-fold higher for treated patients (2000-10000 mg/day) than placebo-treated patients (40-80 mg/day) [11, [22] [23] [24] [25] . However, adverse reactions still remain as the main drawback of treatments. For this reason, restitution of tolerance may be the future for food allergy treatment in patients who do not naturally achieve tolerance [26, 27] , in patients who show an impaired oral and/or systemic tolerance [28] , or in patients with difficulties in avoiding the allergenic food. + cells gated on CD4 + lymphocytes were quantified (histogram) by flow cytometry and transferred to naïve receptor mice. B, Skin test, symptoms scored following the oral challenge and serum CMP-specific IgE in receptor mice. a) Control mice: naïve mice only received PBS iv ; b) Control mice: naïve mice received PBS iv and were sensitized; c) naïve mice received differentiated-Treg and were sensitized. C, In vivoinduced Treg in mice that were orally given daily dose of CMP and then sensitized (CMP prev ). As control, donor mice received daily dose of PBS ig and then were sensitized (PBS prev ). MLN cells were isolated from donor mice and FoxP3 + cells (gated from CD4 + CD25 + lymphocytes) were evaluated and quantified by flow cytometry. D, CD25 depletion was performed on MLN cells and evaluated by flow cytometry. Depleted and not depleted cells were adoptively transferred to receptor mice, which were then sensitized. E, Skin test, symptoms scored following the oral challenge and serum CMP-specific IgE in receptor animals. a) Control mice: naïve recipient mice received PBS iv and then were sensitized; b) Control mice: receptor mice that received MLN cells depleted with a-CD25 isolated from donor PBS prev animals and then were sensitized; c) Receptor mice that received MLN cells depleted with a-CD25 isolated from donor CMP prev animals and then were sensitized; d) Receptor mice that received MLN cells from PBS prev animals treated with isotype control antibody and then were sensitized; e) Receptor mice that received MLN cells from CMP prev animals treated with isotype control antibody and then were sensitized. Results are representative of two independent experiments with similar results. Two-way ANOVA was used because all the data had normal distribution and equal variances ***P<0.001, **P<0.01, *P<0.05. doi:10.1371/journal.pone.0141116.g005
Orally-Induced Treg Control Food Allergy
Although oral immunotherapy show promise for IgE-mediated food allergy in clinical trials, it is not ready for implementation in clinical practice. In this sense, animal models could make relevant contributions for medical research. In our study, using an IgE-mediated food allergy mouse model, we provided evidence that the oral administration of low doses of allergens induced CD4 + CD25 + FoxP3 + cells in the intestinal mucosa, with an increased production of IL-10 and a concomitant suppression of IL-5, IL-13, IgE production and Teff responses. Remarkably, the activation of skin mast cells was abrogated, and the symptoms following an oral exposure to the food allergen were long-term controlled, which may suggest that the induced Tregs controlled mast cell activation or mast cells had low level of bound-IgE. Furthermore, in this work tolerance was achieved with 10 mg of CMP in the preventive protocol, while 10 μg were used in the treatment protocol to reduce the risk of adverse reactions. Most importantly, a higher dose (8-fold increased) of allergen was necessary to promote hypersensitivity symptoms in treated mice compared to sensitized animals. Since animals tolerated an oral challenge with 10 mg of CMP five months after discontinuation of treatment, we can reasonable suggest that acquisition of tolerance was achieved through active suppression. Nevertheless, further studies are essential to understand this long-term management. In this sense, it would be interesting to analyze if the tolerogenic protocols here employed involve the B cell subset. This is a controversial field and it has been demonstrated that the mucosal administration of antigens induces a B cell-dependent T cell-mediated tolerance [29] [30] [31] . Studies conducted by Adel-Patient et al. [32] showed that animals preventively treated with oral β-lactoglobulin, and then intraperitoneally sensitized with the same allergen and alum, had a high frequency of CD4 + CD25 + FoxP3 + cells in MLN, Peyer´s patches and spleen 72 hours after the oral challenge. Yamada et al. [33] described in a rhinitis model that IL-10-expressing CD4 However, no markers of tolerance were shown in the intestinal mucosa. In our work, we observed an increased frequency of regulatory T cells in the gut mucosa to dampen the local inflammation. FoxP3 induces the expression of the anti-inflammatory cytokine IL-10 and supports the maintenance of immunosuppressive milieu [35] . A deregulation of FoxP3+ Treg seems to play an important role in allergic disease since a Treg impaired function has been associated with development of allergy [28, 36, 37] , and mutations in the foxp3 gene induce a severe autoimmunity, polyendocrinopathy and allergy (IPEX) [38] . In our study, the adoptive transfer of Treg prevented the further sensitization with CT and CMP, whereas Treg depletion abrogated this immunomodulation. Syed et al described that oral immunotherapy with peanut allergens was associated with an absence of response to the antigen after a month of therapy. They observed a modification of the FoxP3 methylation pattern and Treg activation [39] . Induction of adaptive Treg (iTreg) and increased secretion of IL-10 and TGF-β have been reported in several studies that employed different antibody-or antibody fraction-based biologicals to prevent or control experimental autoimmunity, through not fully understood mechanisms [40] [41] [42] . In our study, the controlled mucosal administration of antigens rendered an intestinal tolerogenic environment which induced iTreg that prevented or reversed the T cellmediated allergic immune response. This approach may provide a therapeutic alternative to induce active suppression for controlling autoimmune and allergic disorders.
In conclusion, we studied two tolerogenic therapeutic strategies that ameliorated the hypersensitivity symptoms following an oral exposure in sensitized mice. We demonstrated that IL-10-and TGF-β-producing CD4 + CD25 + FoxP3 + mucosal cells were induced with these immunotherapies, thus creating a dominant tolerogenic intestinal environment that suppressed the production of IL-5, IL-13 and IgE.
